NTRA
Natera, Inc.
Diagnostics & Research · Healthcare · United States
414.30
close · 2026-10-30
value
28
cheaper than peers28
quality
66
stronger fundamentals66
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -0.9% | 56 |
| earnings yield, latest year | -0.4% | 53 |
| earnings yield, 3 years ago | -1.3% | 52 |
| cash flow yield, 2 years ago | -0.5% | 50 |
| earnings yield, 1 year ago | -0.4% | 47 |
| cash flow yield, 3 years ago | -0.8% | 47 |
| cash flow yield, 1 year ago | 0.1% | 40 |
| cash flow yield, latest year | 0.1% | 37 |
| price to sales | 23.88× | 8 |
| price to book | 32.67× | 2 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 38.8% | 89 |
| debt to equity | 13.5% | 84 |
| operating margin | -12.4% | 35 |
| return on equity | -15.0% | 26 |
4 of 4 measures available
Facts
| market cap | $60B |
| free cash flow | $136.9M |
| employees | 6,135 |
| first trade | 2015-07-01 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -1.52 | -1.53 | -3.78 | -5.57 | not reported |
| free cash flow | $76.1M | $58.7M | -$286.2M | -$479.2M | not reported |
| net income | -$208.2M | -$190.4M | -$434.8M | -$547.8M | not reported |
| revenue | $2.31B | $1.70B | $1.08B | $820.2M | not reported |
| unusual items | not reported | not reported | not reported | $0 | $0 |